TABLE 2.
Drugs Not Eligible for 2025 Selection for Medicare Drug Price Negotiation
| Rank | Brand name | Generic name | Manufacturer | Gross Part D spending in 2022 | Reason for ineligibility |
|---|---|---|---|---|---|
| 1 | Trulicity | Dulaglutide | Eli Lilly and Co. | $6,225,291,668 | Not eligible for selection until 2028 because of years since approval |
| 2 | Revlimid | Lenalidomide | Bristol Myers Squibb | $5,935,051,092 | Generic approved and marketed |
| 3 | Humira | Adalimumab | AbbVie Inc. | $5,426,379,715 | Biosimilar approved and marketed |
| 4 | Lantus/Toujeo | Insulin glargine | Sanofi | $4,568,969,345 | Biosimilar approved and marketed |
| 5 | Biktarvy | Bictegravir/emtricitabine/tenofovir | Gilead Sciences | $2,703,581,195 | Not eligible for selection until 2028 because of years since approval |
| 6 | Myrbetriq | Mirabegron | Astellas Pharma Inc. | $2,252,501,068 | Generic approved and marketed |
| 7 | Invega | Paliperidone | Janssen Pharmaceuticals | $2,187,077,811 | Generic approved and marketed |
| 8 | Jakafi | Ruxolitinib | Incyte Corp | $1,756,404,369 | Will likely meet small biotech exception |
| 9 | Symbicort | Budesonide/formoterol | AstraZeneca | $1,964,824,955 | Generic approved and marketed |
| 10 | Restasis | Cyclosporine | AbbVie Inc. | $1,722,821,911 | Generic approved and marketed |
| 11 | Tresiba | Insulin degludec | Novo Nordisk | $1,697,272,112 | Not eligible for selection until 2029 because of years since approval |
| 12 | Spiriva | Tiotropium | Boehringer Ingelheim | $1,827,052,606 | Generic approved and marketed |
| 13 | Levemir | Insulin detemir | Novo Nordisk | $1,727,938,074 | Expected to be discontinued by the end of 2024 |
| 14 | Latuda | Lurasidone hydrochloride | Sunovion Pharmaceuticals | $1,448,475,890 | Generic approved and marketed |
| 15 | Ingrezza | Valbenazine | Neurocrine | $1,272,808,746 | Will likely meet small biotech exception |
| 16 | Dupixent | Dupilumab | Regeneron Pharmaceutical | $1,078,090,038 | Not eligible for selection until 2031 because of years since approval |
| 17 | Advair | Fluticasone/salmeterol | GlaxoSmithKline | $1,332,142,779 | Generic approved and marketed |
| 18 | Cabometyx | Cabozantinib | Exelixis, Inc. | $919,262,057 | Will likely meet small biotech exception |
| 19 | Cosentyx | Secukinumab | Novartis | $1,029,748,131 | Not eligible for selection until 2029 because of years since approval |
| 20 | Repatha | Evolocumab | Amgen | $906,530,692 | Not eligible for selection until 2029 because of years since approval |
| 21 | Vyndamax | Tafamidis | Pfizer Inc. | $845,100,487 | Not eligible for selection until 2029 because of years since approval |
| 22 | Erleada | Apalutamide | Janssen Pharmaceuticals | $877,671,428 | Not eligible for selection until 2028 because of years since approval |
The list includes products with projected gross spending in 2023 above $1 billion that do not qualify for selection in 2025. Products selected for negotiation in 2023 are not listed.